Understanding
US regulator expands access to Alzheimer’s drug lecanemab
The US Food and Drug Administration (FDA) has granted full approval to the drug lecanemab (known commercially as Leqembi) for people in the US with confirmed amyloid positivity and a diagnosis of mild cognitive impairment (MCI) or early-stage Alzheimer’s disease.
How discoveries pave the way for improving people’s lives
We recap the British Neuroscience Association conference, where scientists discussed how discoveries in the lab are being transformed into new ways to diagnose and treat the diseases that cause dementia.
Deep-brain stimulation restores memory in mice with Alzheimer’s symptoms
Scientists in the US have found that stimulating precise areas in the brains of mice can help alleviate Alzheimer’s symptoms.
Solving a 30-year mystery – how an important Alzheimer’s risk gene affects our brain
Lots of factors affect a person’s risk of getting Alzheimer’s disease, the number one cause of dementia. It’s a complex mix of lifestyle, health and age, but our genetic makeup plays a particularly important role in determining whether we will get Alzheimer’s.
US regulator grants accelerated approval for Alzheimer’s drug lecanemab
It’s been less than two years since the US Food and Drug Administration (FDA) approved the first licence of a new drug for Alzheimer’s disease in a generation. But that drug, aducanemab, became a source of controversy, and was not approved for use in Europe by the European Medicines Agency (EMA). Now, the US regulator…
Alzheimer’s drug gantenerumab fails to slow decline in phase III clinical trial
The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer’s drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer’s disease.
Could being a ‘superager’ prevent memory and thinking problems in later life?
Research in the US published today (Friday 30 September) suggest that the brain cells of ‘superagers’ may hold the key to resisting memory and thinking problems later in life.
Seven habits reduce dementia risk even with Alzheimer’s risk genes
Researchers in the US have found that people who adopt seven health habits are less likely to develop dementia, regardless of their underlying genetic risk
Amyloid: 30 years of a breakthrough theory
30 years ago Prof John Hardy set out the amyloid cascade hypothesis, giving the foundation for our current understanding of Alzheimer’s.
APOE4: Potential cognitive benefits of the major Alzheimer’s risk gene
Alzheimer’s Research UK funded research has found that having the Alzheimer’s risk gene, APOE4 is linked with better performance on tests of a cognitive skill known as visual working memory.
